EPZ-5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ-5676 (SKU A4166, APExBIO) is a highly selective DOT1L histone methyltransferase inhibitor with an IC50 of 0.8 nM and a Ki of 80 pM, showing >37,000-fold selectivity versus other methyltransferases (APExBIO). It acts as a competitive SAM-site inhibitor and induces potent cytotoxicity in acute leukemia cell lines with MLL translocations. In vivo, EPZ-5676 achieves complete tumor regression in MV4-11 xenograft models at 35–70 mg/kg/day, with no significant weight loss or toxicity. The inhibitor is a solid, stable compound, soluble in DMSO and ethanol, but insoluble in water. It is a validated tool for both biochemical DOT1L inhibition assays and cell-based proliferation studies (Anbazhagan et al. 2024).

Biological Rationale

DOT1L (Disruptor of telomeric silencing 1-like) is a histone methyltransferase that specifically methylates lysine 79 on histone H3 (H3K79). This methylation regulates gene expression, chromatin structure, and cellular differentiation. Aberrant DOT1L activity is implicated in MLL (Mixed Lineage Leukemia) rearranged leukemias. In these leukemias, MLL fusion proteins aberrantly recruit DOT1L, resulting in ectopic H3K79 methylation and activation of leukemogenic gene programs. Inhibition of DOT1L activity suppresses H3K79 methylation, downregulates MLL-fusion target genes, and induces cytotoxicity in MLL-rearranged leukemia cells (Anbazhagan et al. 2024). DOT1L inhibition is a key strategy for targeted epigenetic intervention in cancer.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 binds competitively to the S-adenosyl methionine (SAM) binding pocket of DOT1L. By occupying this site, it prevents transfer of methyl groups to H3K79. The binding of EPZ-5676 induces a conformational change in DOT1L, exposing a hydrophobic pocket beyond the amino acid portion of SAM. This unique binding mode underpins its high selectivity: EPZ-5676 exhibits >37,000-fold selectivity versus CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1 methyltransferases (APExBIO). Inhibition of DOT1L leads to reduced levels of H3K79 methylation. This, in turn, disrupts the expression of MLL-fusion target genes such as HOXA9 and MEIS1, which are critical for leukemic cell survival and proliferation (Further mechanistic insights here; this article extends the mechanistic details with new selectivity benchmarks and updated in vivo data).

Evidence & Benchmarks

• EPZ-5676 displays an IC50 of 0.8 nM and Ki of 80 pM for DOT1L enzymatic inhibition in biochemical assays (buffer: Tris-HCl 50 mM, pH 8.0, 25°C, 30 min) (APExBIO).
• Demonstrates >37,000-fold selectivity over 12 other histone methyltransferases (CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, WHSC1/1L1) in parallel enzyme inhibition panels (Anbazhagan et al. 2024).
• Inhibits proliferation of MV4-11 acute leukemia cells (MLL-rearranged) with an IC50 of 3.5 nM after 4–7 days (RPMI-1640, 10% FBS, 37°C, 5% CO2) (APExBIO).
• Induces complete tumor regression in nude rats bearing MV4-11 xenografts at doses of 35–70 mg/kg/day IV for 21 days, with no significant toxicity or weight loss (Anbazhagan et al. 2024).
• Suppresses H3K79 methylation and downregulates MLL-fusion target genes (e.g., HOXA9, MEIS1) in cell-based and in vivo models (This article updates the protocol reproducibility data highlighted here).

Applications, Limits & Misconceptions

EPZ-5676 is primarily used in:

• Biochemical enzyme inhibition assays targeting DOT1L.
• Cell proliferation and cytotoxicity studies in MLL-rearranged leukemia cell lines (e.g., MV4-11, MOLM13).
• In vivo preclinical models assessing antitumor efficacy and epigenetic modulation.
• Translational research into epigenetic regulation in cancer and potential for combination therapies (Our article clarifies the cancer-versus-fibrosis scope discussed here).

Common Pitfalls or Misconceptions

• EPZ-5676 is not effective in non-MLL-rearranged leukemia models; activity is highly context-dependent.
• Compound is insoluble in water; use DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasound) for stock solutions.
• Long-term storage of solutions at room temperature leads to loss of potency; store below -20°C.
• Not suitable for direct use in clinical protocols; for research use only.
• DOT1L inhibition may not affect pathways regulated by other histone modifications (e.g., HDAC4/5/7, as shown in Anbazhagan et al. 2024).

Workflow Integration & Parameters

For biochemical assays, dissolve EPZ-5676 in DMSO to desired concentration (≥28.15 mg/mL). For cell-based assays, dilute DMSO stocks into culture media; maintain DMSO below 0.1% (v/v) to avoid cytotoxicity. In vivo, administer intravenously at 35–70 mg/kg/day for 21 days for MV4-11 xenograft studies. Store solid at -20°C, protected from light. For best practice in cell viability and proliferation assays, see this guide, which this article extends by incorporating new selectivity and in vivo efficacy data.

Conclusion & Outlook

EPZ-5676 represents a gold standard for selective DOT1L inhibition in MLL-rearranged leukemia research. Its high potency, selectivity, and in vivo efficacy support its use as a benchmark antiproliferative agent and epigenetic tool. Future directions include combination epigenetic therapies and deeper exploration of non-oncology applications. For product specifications and ordering, consult the DOT1L inhibitor EPZ-5676 product page.